Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Envoy Medical Inc (COCH)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$7.10-0.28%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for COCH yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash from operations improves to better than -$6M | A primary condition in Envoy Medical Inc's published investment case. The stated target is >= -6.0 million USD. | Broken | cash from operations falls below -6.0 million USD in any quarter | Cash from operations: $-5.456M FY2026-Q2; GAAP. Published target: >= -6.0 million USD. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 10, 2026-5,456,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative growth, not an established earnings compounder: revenue is minimal and the company remains loss-making. The multi-year thesis is in a watch state, with clinical and regulatory milestones advancing but execution, financing, and industry-relative performance still uncertain.
COCH is valued at a 107.9% premium to peers, and the valuation model has low confidence. The expectations gap is elevated and the valuation tag is unjustified, suggesting that the price reflects meaningful future opportunity despite weak current earnings; evidence on exactly what the market assumes is limited.
Near term, management has reported completing pivotal-trial enrollment and submitting the first PMA module, while operating losses narrowed between the first and second quarters of 2026. Revenue remains very limited, cash declined between those quarters, and ongoing cash use leaves runway execution as a concern; recent performance is below the industry cohort, though it has not freshly broken.
Over the multi-year view, the thesis depends on advancing the clinical trial and PMA process while managing cash through submission. A guidance cut or further weakening in jobs data would add pressure, while continued earnings strength and higher guidance from sector bellwethers could support sector momentum.
COCH has delivered several stated clinical, regulatory, and patent milestones, but losses, limited revenue, cash needs, and a high peer premium leave the long-term thesis fragile. The next evidence on execution and runway matters more than the recent improvement in composite insight. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Operating income remains near -$6M or better | Envoy Medical aims to control losses with operating income near -$6M in 2026-Q1. | Under Pressure | operating income falls below -6.0 million USD in any quarter | Operating income: $-5.569M FY2026-Q2; GAAP. Published target: >= -6.0 million USD. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 10, 2026-5,569,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain Nasdaq listing compliance | Nasdaq compliance efforts continue despite past delisting notices. | Under Pressure | Receipt of new delisting notice or transfer of listing | Qualitative: 1-for-10 reverse split executed to address bid-price compliance Company executed a 1-for-10 reverse stock split on Oct 22, 2026, specifically to address Nasdaq listing compliance issues. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.19 → $-2.35 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.19 | $240,000 | 1 / 1 |
| 2026-07-25 | $-0.19 | $240,000 | 1 / 1 |
| 2026-07-26 | $-0.19 | $240,000 | 1 / 1 |
| 2026-07-27 | $-0.19 | $240,000 | 1 / 1 |
| 2026-07-28 | $-0.19 | $240,000 | 1 / 1 |
| 2026-07-29 | $-0.23 | $100,000 | 1 / 1 |
| 2026-07-30 | $-0.23 | $100,000 | 1 / 1 |
| 2026-07-31 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-01 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-02 | $-0.23 | $320,000 | 2 / 2 |
| 2026-08-03 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-04 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-05 | $-0.23 | $320,000 | 2 / 2 |
| 2026-08-06 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-07 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-08 | $-0.23 | $320,000 | 2 / 2 |
| 2026-08-09 | $-0.23 | $320,000 | 2 / 2 |
| 2026-08-10 | $-0.23 | $320,000 | 2 / 2 |
| 2026-08-11 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-12 | $-0.23 | $320,000 | 2 / 2 |
| 2026-08-13 | $-0.23 | $320,000 | 2 / 2 |
| 2026-08-14 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-15 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-16 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-17 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-18 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-19 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-20 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-21 | $-0.23 | $100,000 | 1 / 1 |
| 2026-08-22 | $-0.22 | $100,000 | 1 / 1 |
| 2026-08-23 | $-0.22 | $100,000 | 1 / 1 |
| 2026-08-24 | $-0.22 | $100,000 | 1 / 1 |
| 2026-08-25 | $-0.22 | $100,000 | 1 / 1 |
| 2026-08-26 | $-0.22 | $100,000 | 1 / 1 |
| 2026-08-27 | $-0.22 | $100,000 | 1 / 1 |
| 2026-08-28 | $-0.22 | $100,000 | 1 / 1 |
| 2026-08-29 | $-0.22 | $100,000 | 1 / 1 |
| 2026-08-30 | $-0.22 | $100,000 | 1 / 1 |
| 2026-08-31 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-01 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-02 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-03 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-04 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-05 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-06 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-07 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-08 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-09 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-10 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-11 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-12 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-13 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-14 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-15 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-16 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-17 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-18 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-19 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-20 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-21 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-22 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-23 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-24 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-25 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-26 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-27 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-28 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-29 | $-0.22 | $100,000 | 1 / 1 |
| 2026-09-30 | $-0.22 | $100,000 | 1 / 1 |
| 2026-10-01 | $-0.22 | $100,000 | 1 / 1 |
| 2026-10-02 | $-0.22 | $100,000 | 1 / 1 |
| 2026-10-03 | $-0.22 | $100,000 | 1 / 1 |
| 2026-10-04 | $-0.22 | $100,000 | 1 / 1 |
| 2026-10-05 | $-0.22 | $100,000 | 1 / 1 |
| 2026-10-06 | $-0.22 | $100,000 | 1 / 1 |
| 2026-10-07 | $-0.22 | $100,000 | 2 / 2 |
| 2026-10-08 | $-0.24 | $133,333 | 2 / 2 |
| 2026-10-09 | $-0.24 | $133,333 | 2 / 2 |
| 2026-10-10 | $-0.24 | $133,333 | 2 / 2 |
| 2026-10-11 | $-0.24 | $133,333 | 2 / 2 |
| 2026-10-12 | $-0.24 | $133,333 | 2 / 2 |
| 2026-10-13 | $-0.24 | $133,333 | 2 / 2 |
| 2026-10-14 | $-0.24 | $266,667 | 2 / 2 |
| 2026-10-15 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-16 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-17 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-18 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-19 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-20 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-21 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-22 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-23 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-24 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-25 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-26 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-27 | $-0.24 | $273,333 | 2 / 2 |
| 2026-10-28 | $-2.35 | $273,333 | 2 / 2 |
| 2026-10-29 | $-2.35 | $273,333 | 2 / 2 |
| 2026-10-30 | $-2.35 | $273,333 | 2 / 2 |
| 2026-10-31 | $-2.35 | $273,333 | 2 / 2 |
| 2026-11-01 | $-2.35 | $273,333 | 2 / 2 |
| 2026-11-02 | $-2.35 | $273,333 | 2 / 2 |
| 2026-11-03 | $-2.35 | $273,333 | 2 / 2 |
| 2026-11-04 | $-2.35 | $273,333 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.